Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia
Minimal residual disease (MRD) is the strongest prognostic factor in both childhood and adult acute lymphoblastic leukemia (ALL). Tumor load reduction during/after induction treatment predicts response to therapy and risk of relapse, and thus guides treatment decisions [1].